From Seeking Alpha
Generex Biotechnology (GNBT) quietly released an 8K SEC filing on May 1st. In this "Current Report" they note:
Generex Biotechnology Corporation (the "Company") has received Special
Access Programme authorization from the Therapeutic Products Directorate of
Health Canada for a patient-specific, physician-supervised treatment of Type-1
Diabetes Mellitus with Generex Oral-lyn™, the Company's proprietary oral insulin
spray product. Health Canada's Special Access Programme [SAP] provides access to
non-marketed drugs for practitioners treating patients with serious or
life-threatening conditions when conventional therapies have failed, are
unsuitable, or unavailable.
The filing states that a Type 1 patient will be allowed access to
Oral-lyn. Her Doctor will record her therapuetic response to Oral-lyn and alert
the Director. Investors in Generex hope that positve results may lead to an
expansion of the program.